The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown
Natural Killer (NK) cell therapy, once a promising beacon for cancer treatment, is now being repositioned as a potential game-changer in the management of autoimmune diseases. Biotech companies, like Artiva Biotherapeutics, are shifting their focus to explore the untapped potential of NK cell
In a significant achievement for GT Biopharma, Inc., the FDA has granted clearance for the company's Investigational New Drug (IND) application for GTB-3650, a novel NK cell engager aimed at treating CD33+ leukemia. This regulatory milestone allows the clinical-stage immuno-oncology company to
The healthcare system's history of unethical practices and ongoing issues has fostered a deep mistrust among minority communities. This mistrust affects everything from routine healthcare appointments to participation in clinical trials. Despite significant efforts to increase diversity, enrollment
Recent clinical advancements by PolTREG, a pioneering Polish biotechnology company, have cast a hopeful light on the treatment of type-1 diabetes (T1D). The company's breakthrough Treg therapy, PTG-007, has shown great promise in fundamentally altering the management of this autoimmune disease. T1D
Huntington’s disease, a genetic disorder that leads to the gradual death of nerve cells in the brain, has long challenged the medical and scientific communities. Traditional treatments have provided only limited symptom relief, pushing the quest for innovative therapies that can alter the disease’s
